ABT
Abbott Laboratories
Is ABT Halal?
Medical devices, diagnostics and healthcare products are generally permissible; March 2026 financial ratios pass, while nutritional and formulation details remain methodology-dependent.
What You Should Know
Abbott makes medical devices, diagnostics, established pharmaceuticals, nutrition products and related healthcare technologies. Its March 31, 2026 filing shows debt at 30.83% of total assets, identifiable liquidity at 6.61%, receivables plus cash at 13.60%, and interest income at 0.95% of quarterly revenue. Abbott does not disclose every product ingredient or screened subcategory as a consolidated prohibited-revenue numerator.
⚠️ Concerns
- •Debt was 30.83% of total assets after long-term borrowing activity
- •Nutritional products and some medicines require product-level ingredient and formulation review
- •Interest income was 0.95% of quarterly revenue
- •Device safety, patient access, pricing, clinical evidence, recalls, supplier labor, privacy and environmental impacts require qualitative review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
34,047 / 110,429
7,295 / 110,429
15,013 / 110,429
106 / 11,164
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 30.83%, liquidity/assets is 6.61%, receivables plus cash/assets is 13.60%, and disclosed interest income is 0.95%; product-level business revenue remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined total-assets ratios pass, but product and ingredient-level business evidence remains incomplete; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined 33% limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Abbott develops medical devices, diagnostics, pharmaceuticals, nutrition products and related healthcare technologies. These are generally permissible healthcare activities, but product-level formulation evidence matters.
Limitation: The filing does not classify every product ingredient, excipient, animal-derived input, clinical use or nutrition category into a universal prohibited-revenue numerator.
Purification
Disclosed interest income is 0.95% of quarterly revenue, but product-level screened business revenue remains unavailable; no fixed purification percentage is prescribed.
Inputs, assumptions and primary sources
- Amounts are USD millions from Abbott's March 31, 2026 Form 10-Q.
- Debt includes current portion of long-term debt of $4,409 million and long-term debt of $29,638 million.
- Cash is $6,803 million. Short-term investments are $492 million; long-term investments of $1,090 million are predominantly equity securities and other investments and are not added to the interest-bearing-security numerator.
- Trade receivables are $8,210 million; prepaid expenses and other receivables are excluded from the narrower trade-receivable input. Quarterly net sales are $11,164 million.
- Disclosed interest income is $106 million for the quarter.
- Abbott reports devices, diagnostics, pharmaceuticals and nutrition products but does not quantify every ingredient or product-specific category as a reproducible prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →